Top Markets
Coin of the day
PreveCeutical Medical Inc. PreveCeutical Medical Inc.

PreveCeutical Medical Inc.

PREV
Kedudukan dalam Saham #33933
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating... PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
Harga Saham
$0.01100905
Disegerakkan terakhir: 2026-08-13
Modal Pasaran
$6.59M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-49.29%
Negara
CA
Perdagangan PreveCeutical Medical Inc. (PREV)

Kategori

Hasil untuk PreveCeutical Medical Inc. (PREV)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada PreveCeutical Medical Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi PreveCeutical Medical Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE